+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Dulaglutide"

Dulaglutide Market Report 2024 - Product Thumbnail Image

Dulaglutide Market Report 2024

  • Report
  • September 2024
  • 175 Pages
  • Global
From
Type 2 Diabetes Market Report 2025 - Product Thumbnail Image

Type 2 Diabetes Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
From
From
From
From
From
From
From
Loading Indicator

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes and obesity. It is a long-acting injectable medication that helps to reduce blood sugar levels by increasing insulin production and decreasing glucagon production. It also helps to reduce appetite and promote weight loss. Dulaglutide is approved by the US Food and Drug Administration (FDA) for use in adults with type 2 diabetes and is available in both brand and generic forms. Dulaglutide is part of the Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat a variety of conditions such as diabetes, obesity, thyroid disorders, and other endocrine and metabolic disorders. The market is expected to grow due to increasing prevalence of endocrine and metabolic disorders, rising awareness of the importance of early diagnosis and treatment, and the availability of new treatments. Some companies in the Dulaglutide market include Eli Lilly, Novo Nordisk, Sanofi, and Merck. Show Less Read more